This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease | MicrobiomeTrials
← Back to trials NCT07509034
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease Recruiting PHASE1 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-06-18Est. Completion: 2030-01-30
Enrollment target: 40 participantsLocations National Institutes of Health Clinical Center, Bethesda, Maryland, United States Other microbiome trials you might be interested in Non Small Cell Lung Cancer
The purpose of this study, known as DISCERN, is to compare two different treatments for a type of lung cancer called non…
Birmingham, United States Est. completion Apr 27, 2027
Extensive Stage Lung Small Cell Cancer
Eligible untreated participants with Extensive Stage Small Cell Lung Cancer (ES-SCLC) who are ≥ 18 years of age will be …
Miami, United States Est. completion Dec 2027